It has been approved for the treatment of active RA on the basis of superior efficacy over methotrexate.40 Notably, phase III trials have suggested increased clinical responses over anti-TNF agents (adalimumab) as early as 2–4 weeks after treatment initiation. Here, TNF is linked to rheumatoid arthritis.